Minor biotech-success heading for patient studies
The Danish biotech company Orphazyme has received financial backing from Novo A/S through all its development phases. Next year the company is ready to take another big step forward.
by Henrik Tüchsen
The small, but well-performing, biotech company Orphazyme expects to enroll patients and initiate phase I/II studies in the late fall of 2013, and everything is going according to plan, says CSO Thomas Kirkegaard Jensen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
